COVID-19 Impact on Global Duchenne Muscular Dystrophy (DMD) Drugs Market

1. Duchenne Muscular Dystrophy (DMD) Drugs Market Report As per the research conducted by GME, the Duchenne Muscular Dystrophy (DMD) Drugs Market will grow with a CAGR value of 41.3 percent by 2026. The global market for Duchenne muscular dystrophy is foreseen to grow due to accelerated research and development activities, expanded patient awareness for effective treatments, and the launch of new medications Moreover, the disease's increasing prominence is likely to drive the global duchenne muscular dystrophy market forward. Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Duchenne Muscular Dystrophy (DMD) Drugs Market - Forecast to 2026" https://www.globalmarketestimates.com/market-report/global-duchenne-muscular-dystrophy-dmd-drugs- market-3126 By Therapeutic Approach (Mutation Suppression, Exon Skipping, and Steroid Therapy), By Product Type (Corticosteroids and Pain Management Drugs), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); Company Market Share Analysis, End-User Landscape, and Competitor Analysis. Key Market Insights The rising expenditures in biopharmaceutical research & development activities to launch new clinical treatments are driving the development of the Duchenne muscular dystrophy (DMD) treatment market. Corticosteroids are leading as per the product type because theyaid in the maintenance of pulmonary and cardiovascular functionality during the non-ambulatory period of DMD. Mutation suppression is leading in the therapeutic approach segment because it addresses the underlying gene that causes muscular dystrophy. North America predominates the Duchenne muscular dystrophy market because of the increase in clinical trials for this field. Italfarmaco S.p.A., FibroGen, Inc., Summit Therapeutics Plc, PTC Therapeutics, Santhera Pharmaceuticals, Sarepta Therapeutics, Inc., NS Pharma, Inc., Wave Life Sciences, Daiichi Sankyo Company, Pfizer Inc., Solid Biosciences, amongst others, are the major players in the Duchenne muscular dystrophy (DMD) drugs market.

2. Browse the Report @ https://www.globalmarketestimates.com/market-report/global-duchenne-muscular- dystrophy-dmd-drugs-market-3126 Therapeutic Approach Type Outlook (Revenue, USD Billion, 2021-2026) Mutation Suppression Exon Skipping Steroid Therapy Product Outlook (Revenue, USD Billion, 2021-2026) Corticosteroids Pain management drugs Regional Outlook (Revenue, USD Billion, 2021-2026) North America The U.S. Canada Mexico Europe Germany UK France Spain Italy Rest of Europe Asia Pacific China India Japan South Korea Australia Rest of APAC Central & South America

3. Brazil Argentina Rest of CSA Middle East & Africa Saudi Arabia UAE Rest of MEA Contact: Tracy Simon Email address: tracy.simon@globalmarketestimates.com Phone Number: +16026667238 Website: https://www.globalmarketestimates.com/ Check our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php